HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphoma.

Abstract
The treatment of malignant lymphoma has improved over the past 20 years, but the majority of patients are not cured. New modalities using targeted therapy based on new information in molecular biology and immunology hold promise for better outcomes with less toxicity. We review data on the use of radiolabeled monoclonal antibodies directed against the CD20 antigen on malignant B cells. We discuss the major radionuclides available, iodine 131 ((131)I), tositumomab, and yttrium 90 ((90)Y) ibritumomab tiuxetan (Zevalin; IDEC Pharmaceuticals, San Diego, CA) and present data on new approaches in labeling antibodies that have facilitated their use. Clinical trial data with the yttrium-labeled antibodies are discussed. The use of dosimetry as a means for predicting toxicity is discussed, and the questions of long-term toxicity (late effects) are addressed. These targeted approaches to the treatment of malignancy, and lymphoma in particular, hold great promise.
AuthorsLeo I Gordon, Thomas E Witzig, Greg A Wiseman, Ian W Flinn, Stewart S Spies, Daniel H Silverman, Christos Emmanouilides, Larry Cripe, Mansoor Saleh, Myron S Czuczman, Teresa Olejnik, Christine A White, Antonio J Grillo-López, Christos Emmanuolides
JournalSeminars in oncology (Semin Oncol) Vol. 29 Issue 1 Suppl 2 Pg. 87-92 (Feb 2002) ISSN: 0093-7754 [Print] United States
PMID11842394 (Publication Type: Journal Article, Review)
CopyrightCopyright 2002 by W.B. Saunders Company.
Chemical References
  • Antibodies, Monoclonal
  • Antigens, CD20
  • Iodine Radioisotopes
  • Radiopharmaceuticals
  • Yttrium Radioisotopes
  • ibritumomab tiuxetan
  • tositumomab I-131
Topics
  • Antibodies, Monoclonal (therapeutic use)
  • Antigens, CD20
  • Clinical Trials as Topic
  • Humans
  • Iodine Radioisotopes (therapeutic use)
  • Lymphoma, B-Cell (radiotherapy)
  • Lymphoma, Non-Hodgkin (radiotherapy)
  • Quality of Life
  • Radioimmunotherapy
  • Radiopharmaceuticals (therapeutic use)
  • Radiotherapy Dosage
  • Yttrium Radioisotopes (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: